Key Points
Oppenheimer maintains Outperform rating, raises RLAY price target to $18 from $14
Stock declines 12.84% to $13.03 despite analyst confidence and 38% upside potential
Wall Street consensus shows 9 Buy ratings with no Sell recommendations on Relay Therapeutics
Clinical-stage biotech with three lead programs in oncology and genetic disease, backed by Genentech partnership
Oppenheimer maintained its Outperform rating on Relay Therapeutics (RLAY) on April 28, 2026, while raising the price target to $18 from $14. This action reflects analyst confidence in the clinical-stage biotech company’s precision medicine pipeline. RLAY trades at $13.03, down 12.84% from the previous close of $14.95. The stock has a market cap of $2.33 billion. Despite recent weakness, the analyst upgrade signals potential upside for investors tracking this Cambridge-based oncology and genetic disease specialist.
Oppenheimer’s Maintained Outperform Rating and Price Target Increase
Rating Action and Target Adjustment
Oppenheimer kept its Outperform rating intact while raising the price target to $18 from $14, representing 38% upside from current levels. This maintained rating reflects the analyst’s continued belief in RLAY’s clinical pipeline and long-term value creation potential. The price target increase signals growing confidence in the company’s ability to advance its lead programs through development stages.
Market Context for the Rating
The Relay Therapeutics price target raised to $18 from $14 at Oppenheimer comes as the stock faces near-term headwinds. RLAY has declined 12.84% in a single day, trading at $13.03 versus the prior close of $14.95. Despite this volatility, the maintained Outperform stance suggests the analyst views current weakness as a buying opportunity for long-term investors focused on clinical trial progression.
Relay Therapeutics Pipeline and Clinical Development Status
Lead Product Candidates in Development
Relay Therapeutics operates as a clinical-stage precision medicines company with three main programs. RLY-4008 is an oral FGFR2 inhibitor in first-in-human trials for advanced FGFR2-altered solid tumors. RLY-2608 targets mutant-PI3Ka in oncology indications. RLY-1971, developed with Genentech, is a Phase 1 oral small molecule inhibitor of SHP2 in advanced solid tumors. These programs address significant unmet needs in targeted oncology.
Strategic Partnerships and Collaborations
The company maintains key partnerships with D.E. Shaw Research for computational drug discovery and with Genentech for RLY-1971 development and commercialization. These collaborations strengthen RLAY’s ability to advance precision medicine approaches. The company employs 259 full-time employees and is headquartered in Cambridge, Massachusetts, positioning it within the biotech hub ecosystem.
Financial Metrics and Analyst Consensus
Current Valuation and Key Metrics
Relay Therapeutics has a market cap of $2.33 billion with 178.7 million shares outstanding. The stock trades at a price-to-book ratio of 3.95x and price-to-sales of 152.1x, reflecting typical biotech valuations for clinical-stage companies. The company reported negative earnings per share of -$1.61 and a negative PE ratio of -8.09, consistent with pre-revenue biotech profiles. Cash per share stands at $3.23, providing runway for clinical development.
Broader Analyst Consensus
Wall Street consensus shows 9 Buy ratings with no Sell or Hold ratings on RLAY, according to Meyka AI’s stock analysis platform. The consensus rating is 4.0 (Buy). Meyka AI rates RLAY with a grade of B, suggesting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Stock Performance and Technical Outlook
Recent Price Action and Volatility
RLAY has experienced significant volatility recently, declining 12.84% in one day to $13.03. The 52-week range spans $2.67 to $17.32, showing substantial recovery from lows. Year-to-date performance is +54%, while one-year performance stands at +299.7%, reflecting strong long-term momentum despite near-term pullbacks. Trading volume reached 6.6 million shares, above the average of 3.0 million, indicating active investor interest.
Technical Indicators and Momentum
Technical analysis shows mixed signals. The RSI at 45.54 suggests neutral momentum, while the ADX at 49.13 indicates a strong downtrend. The CCI at -171.29 signals oversold conditions, potentially attractive for contrarian buyers. Bollinger Bands show the stock trading near the lower band at $10.77, with the middle band at $14.50. These technical levels suggest potential support and possible mean reversion opportunities.
Final Thoughts
Oppenheimer maintained an Outperform rating and raised Relay Therapeutics’ price target to $18, reflecting 38% upside potential. The analyst confidence stems from the precision medicine pipeline, particularly RLY-4008, RLY-2608, and RLY-1971. Wall Street consensus is constructive with 9 Buy ratings and no Sell recommendations. However, investors must weigh the company’s pre-revenue status, negative cash flow, and clinical-stage risks. Current stock weakness may present an entry opportunity for long-term believers, though biotech volatility remains high. Monitor upcoming clinical trial data and May 4, 2026 earnings announcements.
FAQs
Oppenheimer maintains an Outperform rating on RLAY with a $18 price target, raised from $14 on April 28, 2026. This represents 38% upside and reflects analyst confidence in the company’s clinical pipeline and long-term value creation.
RLAY’s lead programs include RLY-4008 (FGFR2 inhibitor in first-in-human trials), RLY-2608 (mutant-PI3Ka inhibitor), and RLY-1971 (SHP2 inhibitor in Phase 1 with Genentech). All target oncology and genetic disease indications with significant unmet medical needs.
Wall Street consensus shows 9 Buy ratings with no Sell or Hold ratings, yielding a 4.0 Buy rating. Meyka AI assigns RLAY a B grade with a Hold suggestion, considering sector performance and financial metrics.
RLAY fell 12.84% to $13.03 despite Oppenheimer’s maintained Outperform rating, likely due to broader biotech sector weakness or profit-taking. The stock remains 54% higher year-to-date and 299.7% higher over one year.
RLAY has a market cap of $2.33 billion with 178.7 million shares outstanding. The company reports negative EPS of -$1.61 and cash per share of $3.23, typical for clinical-stage biotech companies.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)